| Ann T Boutwell, RN | |
|
2624 9th Ave S, Fargo, ND 58103-2350 | |
| (701) 298-4500 | |
| (701) 298-4400 |
| Full Name | Ann T Boutwell |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 2624 9th Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083030175 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | R37448 (North Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ann T Boutwell, RN 2624 9th Ave S, Fargo, ND 58103-2350 Ph: (701) 298-4500 | Ann T Boutwell, RN 2624 9th Ave S, Fargo, ND 58103-2350 Ph: (701) 298-4500 |
News Archive
Observational studies over the past 30 years suggest that subclinical thyroid disease during pregnancy may be associated with adverse outcomes, including a lower-than-normal IQ in offspring.
Physical fitness and regular exercise reduces a major predictor of cardiovascular disease in adults with normal blood pressure or mild hypertension. Physical conditioning in the absence of medication is not, however, as advantageous to the more severe hypertensive patient, reported researchers at the American Society of Hypertension Twentieth Annual Scientific Meeting.
Outreach Services, a leading provider of patient eligibility and healthcare financial services to U.S. hospitals, announced today a new contract to provide Riverview Hospital Association in Wisconsin Rapids with Medical Assistance Advocacy for uninsured patients.
A commercial vaccine for cattle can effectively reduce levels of E. coli by more than 50 percent, a Kansas State University study has found. The vaccine is also effective using two doses instead of the recommended three doses, which can help cut costs for the beef industry.
Onconova Therapeutics, Inc., announced today the advancement of the oral formulation of rigosertib, an anti-cancer agent with demonstrated activity in solid tumors and hematologic malignancies, into a new Phase II study. The intravenous (IV) formulation of rigosertib is currently in a pivotal Phase III trial for refractory myelodysplastic syndromes (MDS) in the U.S. and EU.
› Verified 2 days ago
Peggy Ann Reinke, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 4255 30th Ave S, Fargo, ND 58104 Phone: 701-478-8122 | |
Jazmyn Rhea Hogenson, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 402 31st Ave N Apt 208, Fargo, ND 58102 Phone: 701-412-3541 | |
Rachel Myers, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1720 University Dr S, Fargo, ND 58103 Phone: 701-234-2000 | |
Kimberly Crandall, RN, BSN, CDE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2400 32nd Ave S, Fargo, ND 58103 Phone: 701-234-2245 Fax: 701-234-8717 | |
Ms. Anne Marie Hersch, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1240 25th St S, Fargo, ND 58103 Phone: 701-241-1360 Fax: 701-241-8559 | |
Amber Fish, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1240 25th St S, Fargo, ND 58103 Phone: 701-241-1360 | |
James Merle Gullekson, LMT Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 4501 15th Ave S Ste 104, Fargo, ND 58103 Phone: 701-446-8833 |